Boehringer Ingelheim Signs Option to Acquire Immunology Partner, Trutino Biosciences

Two years after partnering with Trutino Biosciences on the development of new cancer immunotherapeutics, Boehringer Ingelheim signed an option to acquire its San Diego-based collaborator for an undisclosed amount of money if certain milestones under its existing partnership are achieved.